Low-dose ranibizumab as primary treatment of posterior type I retinopathy of prematurity.

CONCLUSIONS: A single intravitreal dose of 0.2 mg (0.02 mL) ranibizumab showed favourable anatomical and functional outcomes in eyes with type 1 ROP.
PMID: 28985806 [PubMed - in process]

Source: Canadian Journal of Ophthalmology - October 1, 2017 Category: Opthalmology Authors: Ells AL, Wesolosky JD, Ingram AD, Mitchell PC, Platt AS Tags: Can J Ophthalmol Source Type: research